Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2015

01-04-2015 | Epidemiology

The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer

Authors: C. Villarreal-Garza, J. N. Weitzel, M. Llacuachaqui, E. Sifuentes, M. C. Magallanes-Hoyos, L. Gallardo, R. M. Alvarez-Gómez, J. Herzog, D. Castillo, R. Royer, Mohammad Akbari, F. Lara-Medina, L. A. Herrera, A. Mohar, S. A. Narod

Published in: Breast Cancer Research and Treatment | Issue 2/2015

Login to get access

Abstract

Various guidelines recommend that women with triple-negative breast cancer should be tested for BRCA1 mutations, but the prevalence of mutations may vary with ethnic group and with geographic region, and the optimal cutoff age for testing has not been established. We estimated the frequencies of BRCA1 and BRCA2 (BRCA) mutations among 190 women with triple-negative breast cancer, unselected for family history, diagnosed at age 50 or less at a single hospital in Mexico City. Patients were screened for 115 recurrent BRCA mutations, which have been reported previously in women of Hispanic origin, including a common large rearrangement Mexican founder mutation (BRCA1 ex9-12del). A BRCA mutation was detected in 44 of 190 patients with triple-negative breast cancer (23 %). Forty-three mutations were found in BRCA1 and one mutation was found in BRCA2. Seven different mutations accounted for 39 patients (89 % of the total mutations). The Mexican founder mutation (BRCA1 ex9-12del) was found 18 times and accounted for 41 % of all mutations detected. There is a high prevalence of BRCA1 mutations among young triple-negative breast cancer patients in Mexico. Women with triple-negative breast cancer in Mexico should be screened for mutations in BRCA1.
Literature
1.
2.
Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J (2008) Breast cancer in Mexico: a pressing priority. Reprod Health Matters 16:113–123CrossRefPubMed
3.
Chavarri-Guerra Y, Villarreal-Garza C, Liedke PE et al (2012) Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol 13:e335–e343CrossRefPubMed
4.
Weissman BE, Saxon PJ, Pasquale SR, Jones GR, Geiser AG, Stanbridge EJ (1987) Introduction of a normal human chromosome 11 into a Wilms’ tumor cell line controls its tumorigenic expression. Science 236:175–180CrossRefPubMed
5.
Rodriguez-Cuevas S, Guisa-Hohenstein F, Labastida-Almendaro S (2009) First breast cancer mammography screening program in Mexico: initial results 2005-2006. Breast J 15:623–631CrossRefPubMed
6.
Mohar A, Bargallo E, Ramirez MT, Lara F, Beltran-Ortega A (2009) Available resources for the treatment of breast cancer in Mexico. Salud Publica Mex 51(Suppl 2):s263–s269PubMed
7.
Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D et al (2011) Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117:3658–3669CrossRefPubMed
8.
Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC et al (2013) Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist 18(Suppl):26–34CrossRefPubMed
9.
Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMed
10.
Solano AR, Aceto GM, Delettieres D et al (2012) BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus 1:20CrossRefPubMedCentralPubMed
11.
Gomes MC, Costa MM, Borojevic R et al (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103:349–353CrossRefPubMed
12.
Gonzalez-Hormazabal P, Gutierrez-Enriquez S et al (2011) Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Breast Cancer Res Treat 126:705–716CrossRefPubMed
13.
Hernandez JE, Llacuachaqui M, Palacio GV et al (2014) Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellin, Colombia. Hered Cancer Clin Pract 12:11CrossRefPubMedCentralPubMed
14.
Gutierrez Espeleta GA, Llacuachaqui M, Garcia-Jimenez L et al (2012) BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. Clin Genet 82(5):484–488CrossRefPubMed
15.
Vidal-Millan S, Taja-Chayeb L, Gutierrez-Hernandez O et al (2009) Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. Eur J Gynaecol Oncol 30:527–530PubMed
16.
Calderón-Garcidueñas AL, Ruiz-Flores P, Cerda-Flores RM, Barrera-Saldaña HA (2005) Clinical follow up of Mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Salud Publica Mex 47(2):110–115CrossRefPubMed
17.
Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V et al (2012) Full-Exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS ONE 7:e37432CrossRefPubMedCentralPubMed
18.
19.
Torres-Mejia G, Royer R, Llacuachaqui M, et al (2014) Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer. Cancer Epidemiol Biomark Prev
20.
Delgado L, Fernandez G, Grotiuz G et al (2011) BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Res Treat 128(1):211–218CrossRefPubMed
21.
Lara K, Consigliere N, Perez J, Porco A (2012) BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res 45:117–130CrossRefPubMed
22.
Narod SA (2009) Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective. Salud Publica Mex 51(Suppl 2):s191–s196CrossRefPubMed
23.
Weitzel JN, Lagos V, Blazer KR et al (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomark Prev 14:1666–1671CrossRef
24.
Weitzel JN, Lagos VI, Herzog JS et al (2007) Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomark Prev 16:1615–1620CrossRef
25.
Weitzel JN, Clague J, Martir-Negron A et al (2013) Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 31:210–216CrossRefPubMedCentralPubMed
26.
Gallardo M, Silva A, Rubio L et al (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat 95:81–87CrossRefPubMed
27.
Torres D, Rashid MU, Gil F et al (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103:225–232CrossRefPubMed
28.
Vogel KJ, Atchley DP, Erlichman J et al (2007) BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25:4635–4641CrossRefPubMed
29.
Jara L, Ampuero S, Santibanez E et al (2004) Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families. Biol Res 37:469–481CrossRefPubMed
30.
Diez O, Osorio A, Duran M et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301–312CrossRefPubMed
31.
de la Hoya M, Gutierrez-Enriquez S, Velasco E et al (2006) Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clin Chem 52:1480–1485CrossRefPubMed
32.
Blesa JR, Garcia JA, Ochoa E (2000) Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. Hum Mutat 15:381–382CrossRefPubMed
33.
Campos B, Diez O, Domenech M et al (2001) BRCA2 mutation analysis of 87 Spanish breast/ovarian cancer families. Ann Oncol 12:1699–1703CrossRefPubMed
34.
Green ED, Olson MV (1990) Chromosomal region of the cystic fibrosis gene in yeast artificial chromosomes: a model for human genome mapping. Science 250:94–98CrossRefPubMed
35.
Hall MJ, Reid JE, Burbridge LA, Pruss D, Deffenbaugh AM et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast -ovarian cancer. Cancer 115(10):2222–2233CrossRefPubMedCentralPubMed
36.
Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C (2003) Breast cancer genetics in African Americans. Cancer 97(1 Suppl):236–245CrossRefPubMed
37.
Donenberg T, Lunn J, Curling D et al (2011) A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat 125:591–596CrossRefPubMed
38.
Breast Cancer Information Core (BIC). An open access online breast cancer mutation data base. 2010
39.
Vega A, Campos B, Bressac-De-Paillerets B et al (2001) The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 17:520–521CrossRefPubMed
40.
Jara L, Ampuero S, Santibanez E et al (2006) BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 166:36–45CrossRefPubMed
41.
Abugattas J, Llacuachaqui M, Allende YS et al (2014) Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet. doi:10.​1111/​cge.​12505 PubMed
42.
Torres D, Umaña A, Robledo JF et al (2009) Estudio de factores genéticos para cáncer de mama en Colombia, Spanish. Univ Med Bogotá (Colombia) 50:297–301
43.
Martinez ME ea. Family history of breast and ovarian cancer prevalence and its association with triple negative subtype in hispanic women. American Association for Cancer Research Science of Cancer Health Disparities Meeting; San Antonio, TX November 9–12, 2014
44.
Young SR, Pilarski RT, Donenberg T et al (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86CrossRefPubMedCentralPubMed
45.
46.
Gonzalez-Angulo AM, Timms KM et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer, February 22. Clin Cancer Res 17(5):1082–1089CrossRefPubMedCentralPubMed
47.
Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol In press
48.
Byrski T, Huzarski T, Dent R et al (2014) Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147:401–405CrossRefPubMed
49.
Huzarski T, Byrski T, Gronwald J et al (2013) Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31:3191–3196CrossRefPubMed
50.
Metcalfe K, Gershman S, Ghadirian P et al (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348:g226CrossRefPubMedCentralPubMed
Metadata
Title
The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer
Authors
C. Villarreal-Garza
J. N. Weitzel
M. Llacuachaqui
E. Sifuentes
M. C. Magallanes-Hoyos
L. Gallardo
R. M. Alvarez-Gómez
J. Herzog
D. Castillo
R. Royer
Mohammad Akbari
F. Lara-Medina
L. A. Herrera
A. Mohar
S. A. Narod
Publication date
01-04-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3312-8

Other articles of this Issue 2/2015

Breast Cancer Research and Treatment 2/2015 Go to the issue

Epidemiology

The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes

Preclinical Study

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial

Preclinical Study

Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process

Preclinical Study

PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients

Preclinical study

High tumor budding stratifies breast cancer with metastatic properties

Epidemiology

Smoking and survival in female breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits